Here’s what’s challenging the HIV market

Many patients rely on older therapies due to insurance limitations.

High costs and a lack of treatment access continue to hinder progress in the human immunodeficiency virus (HIV) market despite developments in antiretroviral therapy, according to GlobalData.

“In Japan, high costs and limited availability of generic pre-exposure prophylaxis (PrEP) options have made these tools inaccessible for most,” the report said.

Moreover, many patients, even in high-income countries, are forced to rely on older, less convenient therapies due to insurance limitations or out-of-pocket costs, said Abigail Harris, Infectious Disease Analyst at GlobalData.

Underfunding of prevention programmes, limited integration of mental health services, adherence challenges, and affordability barriers also remain key obstacles to achieving HIV control and reducing transmission.

“Targeted investment is needed to expand PrEP access, normalise HIV testing, and support earlier diagnosis,” Harris added.